The Many New Facets of Immune Thrombocytopenia
This program is sponsored by Hemedicus, Inc., and supported by Amgen, Inc.
| Location: |
Peabody Orlando Hotel, Grand Ballroom R |
| Speakers: |
Drew Provan, MD, Barts and the London NHS Trust, London, United Kingdom
Howard A. Liebman, MD, Keck School of Medicine of the University of Southern California, Los Angeles, CA
Terry Gernsheimer, MD, University of Washington School of Medicine, Seattle, WA
David J. Kuter, MD, PhD, Dana-Farber/Harvard Cancer Center, Boston, MA
Roberto Stasi, MD, “Regina Apostolorum” Hospital, Albano Laziale, Rome, Italy
James B. Bussel, MD, Weill Medical College of Cornell University, New York, NY
|
This symposium will discuss new recommendations using didactic presentations and case studies to illustrate how physicians can implement the updated treatment guidelines on diagnosing and treating adults, children, and pregnant patients with immune thrombocytopenia.
Contact: Robin Simak, Hemedicus, Inc.
Phone: 201-666-4700
Fax: 201-666-4747
E-mail: rsimak@hemedicus.com
back to top
Practical Approaches to the Patient With Chronic Myelogenous Leukemia
This program is sponsored by the Educational Concepts Group, LLC, and supported by Bristol-Myers Squibb Company.
| Location: |
Orange County Convention Center, Valencia A |
| Speakers: |
Neil Shah, MD, PhD, University of California – San Francisco School of Medicine, San Francisco, CA
Michael Deininger, MD, PhD, Oregon Health and Science University, Portland, OR
Jorge E. Cortes, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Timothy Hughes, MD, MBBS, University of Adelaide, Australia
Moshe Talpaz, MD, University of Michigan, Ann Arbor, MI
John M. Goldman, DM, Imperial College London, United Kingdom
|
This symposium will be presented in a live, interactive format designed specifically to reinforce key learning objectives. To maximize audience participation, an audience response system will be utilized after each 15-30 minutes of lecture.
Contact: Tina B. Stacy, Educational Concepts Group, LLC
Phone: 770-933-1684
Fax: 770-933-1692
E-mail: tstacy@educationalconcepts.net
back to top
"National NHL Tumor Board:" Clinical Investigators Provide Their Perspectives on Current Cases of Non-Hodgkin Lympohoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This program is sponsored by Cephalon, Inc., Genentech BioOncology/Biogen Idec, and Mellenium Pharmaceuticals, Inc.
| Location: |
Orange County Convention Center, Hall F5 |
| Speakers: |
Myron S. Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY
Jonathan W. Friedberg, MD, MMSc, James P. Wilmot Cancer Center, Rochester, NY
Stephanie A. Gregory, MD, Rush University Medical Center/Rush University, Chicago, IL
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
Mathias J. Rummel, MD, PhD, Hospital of the Justus- Liebig University, Giessen, Germany
Mitchell R. Smith, MD, PhD, Fox Chase Cancer Center, Philadelphia, PA
|
This activity will focus on the multidisciplinary management of NHL. The activity will seek to uncover cases of CLL, follicular lymphoma, diffuse large B-cell lymphoma, and mantle-cell lymphoma that are currently challenging community-based multidisciplinary treatment teams across the United States. In addition, it will offer expert faculty consultation about these diseases in juxtaposition to relevant late-breaking clinical research results.
Contact: Courtney Lohmann, Research to Practice
Phone: 305-400-7306
Fax: 800-960-2944
E-mail: clohmann@researchtopractice.com
back to top
| This symposium has been cancelled. |
AML and MDS: Improving Outcomes Through Process in Biology and Therapy – Clinical Challenges and Interactive Case Presentations
This program is sponsored by the Educational Concepts Group, LLC, and supported by Eisai, Inc.
| Location: |
Orange County Convention Center, Room 109 B |
| Speakers: |
Hagop M. Kantarjian, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Jean-Pierre Issa, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Gary J. Schiller, MD, University of California – Los Angeles, Los Angeles, CA
Judith E. Karp, MD, The Johns Hopkins University, Baltimore, MD
Harry P. Erba, MD, PhD, University of Michigan, Ann Arbor, MI
Eric J. Feldman, MD, Weill Medical College of Cornell University, New York, NY
Jeffrey R. Schriber, MD, Banner Good Samaritan Medical Center, New York, NY
|
As the Educational Concepts Group remains committed to understanding AML and MDS and changing how they are treated, this unique program provides an ideal forum for sharing information and ideas about new approaches to therapy. This program will be presented by prominent, well-respected opinion leaders in AML and MDS. This live, independent educational program will provide medical oncologists, hematologist-oncologists, and hematologists caring for patients with AML and MDS with pertinent information about management issues and treatment strategies.
Contact: Tina B. Stacy, Educational Concepts Group, LLC
Phone: 770-933-1684
Fax: 770-933-1692
E-mail: tstacy@educationalconcepts.net
back to top
Significance of the Tumor Microenvironment in Hematologic Malignancies
This program is sponsored by the Postgraduate Institute of Medicine and supported by Millenium: The Takeda Oncology Company, Celgene, Inc., Allos Therapeutics, and the Leukemia & Lymphoma Society.
| Location: |
Rosen Centre Hotel, Grand Ballroom DE |
| Speakers: |
Sean Morrison, MD, University of Michigan, Ann Arbor, MI
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD
John DiPersio, MD, PhD, Washington University, St. Louis, MO
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA
Iannis Aifantis, PhD, New York University Medical Center, New York, NY
|
This activity is designed to educate hematologists and oncologists on the evolving role of the tumor microenvironment in the pathogenesis and management of various malignancies. Participants will learn about complex interactions between stromal and tumor cells; the role of the bone marrow microenvironment in leukemia; mechanisms by which stroma confer cancer chemotherapy resistance; and the therapeutic potential of targeting various stromal components to overcome resistance and improve outcomes.
Contact: Jeanne Fryar, Robert Michael Educational Institute
Phone: 856-672-3354
Fax: 856-546-7030
E-mail: jfryar@rmei.com
back to top
Challenging Cases in Multiple Myeloma: A Dialogue Between Community and Academic Clinicians to Improve Patient Care and Outcomes
This program is sponsored by the University of Cincinnati and supported by the Millenium: The Takeda Oncology Company.
| Location: |
Rosen Centre Hotel, Grand Ballroom AB |
| Speakers: |
Sundar Jaganath, MD, St. Vincent’s Comprehensive Cancer Center, New York, NY
Jonathan Kaufman, MD, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA
Stefan Knop, MD, University of Wüerzburg, Wüerzburg, Germany
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA
G. David Roodman, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
|
This symposium will serve as a forum to discuss current questions and concerns regarding the treatment and management of patients through the multiple myeloma life cycle. A panel of domestic and international myeloma experts will be joined by representatives from community cancer care facilities and private oncology practices. This symposium will provide evidence-based treatment and management recommendations and address new treatment regimens and management strategies based on recent clinical trials and emerging data. In addition to considering differences in domestic and international care, barriers and/or limitations faced by community cancer centers and private practice oncologists will be debated.
Contact: Linda M. Ritter, Center of Excellence Media, LLC
Phone: 732-992-1885
Fax: 732-992-1881
E-mail: linda@coexm.com
back to top
Management of Elective Surgery in Patients with Hemophilia
This program is sponsored by the American Academy of CME, Inc., and supported by Novo Nordisk, Inc.
| Location: |
Peabody Orlando Hotel, Orlando Ballroom |
| Speakers: |
Christopher A. Ludlam, MB, ChB, PhD, University of Edinburgh, Edinburgh, United Kingdom
Adolpho Llinás, MD, Fundación Santa Fe de Bogotá and Fundación Cosme y Damián, Bogotá, Columbia
Mark Reding, MD, University of Minnesota, Minneapolis, MN
|
Most patients with hemophilia, including those with high-titer inhibitors, have the prospect of a normal lifespan. As these patients age, however, arthropathy and joint deformities can have an increasingly detrimental effect on their quality of life. Although hemophilia was once considered to be a contraindication to elective surgery, access to clotting factor concentrates and bypassing agents has made major elective surgery feasible and generally successful, even for patients with inhibitors. This symposium will consist of three lectures given by experts in the field of elective surgery for patients with hemophilia, followed by a question-and-answer period.
Contact: Peter Macholdt, Scherer Clinical Communications
Phone: 609-466-6458
Fax: 609-466-6459
E-mail: pmacholdt@schereclin.com
back to top
Moving Towards Personalized Medicine in Hematologic Malignancies
This program is sponsored by Hemedicus, Inc., and supported by Seattle Genetics, Inc., Amgen, Inc., and Becton, Dickinson and Company.
| Location: |
Peabody Orlando Hotel, Plaza International Ballroom DEF |
| Speakers: |
Peter van der Spek, PhD, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, Netherlands
Malik Juweid, MD, University of Iowa Hospitals and Clinics, Iowa City, IA
Volker Diehl, MD, PhD, German Hodgkin Study Group, University of Cologne, Cologne, Germany
Andre Goy, MD, Hackensack University Medical Center, Hackensack, NJ
Rafael Fonseca, MD, Mayo Clinic, Scottsdale, AZ
Martin S. Tallman, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
|
This symposium focuses on optimizing treatment decisions in Hodgkin and non-Hodgkin lymphomas, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes, taking into consideration the increasingly obvious molecular heterogeneity of patients.
Contact: Robin Simak, Hemedicus, Inc.
Phone: 201-666-4700
Fax: 201-666-4747
E-mail: rsimak@hemedicus.com
back to top
